Zobrazeno 1 - 10
of 594
pro vyhledávání: '"J. Adelstein"'
A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer
Autor:
Andrew J. Frankart, Nooshin Hashemi Sadraei, Brad Huth, Kevin P. Redmond, William L. Barrett, Nicky Kurtzweil, Muhammad K. Riaz, Trisha Wise‐Draper, Cristina P. Rodriguez, David J. Adelstein, Vinita Takiar
Publikováno v:
Laryngoscope Investigative Otolaryngology, Vol 7, Iss 2, Pp 437-443 (2022)
Abstract Objectives Cisplatin‐based chemoradiation is an established organ‐preserving strategy for locally advanced laryngeal cancer, but long‐term survival remains suboptimal. Immunotherapy has been studied in the metastatic and unresectable r
Externí odkaz:
https://doaj.org/article/d8499775fe624b01ae88778a9faaa52a
Autor:
Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku, Joseph Scharpf, Brandon L. Prendes, Nikhil P. Joshi, Jimmy J. Caudell, Farzan Siddiqui, Sandro V. Porceddu, Nancy Lee, Larisa Schwartzman, Shlomo A. Koyfman, David J. Adelstein, Jessica L. Geiger
Publikováno v:
Current Oncology, Vol 28, Iss 4, Pp 2409-2419 (2021)
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, con
Externí odkaz:
https://doaj.org/article/6936c992016a4b2ca14823b8e16083d3
Autor:
Maxwell Y. Lee, Jonathan Lee, Sarah Stock, Mario Belfiglio, Brian Matia, Shlomo Koyfman, Nikhil P. Joshi, Brian B. Burkey, Eric Lamarre, Brandon Prendes, Joseph Scharpf, Robert R. Lorenz, Neil M. Woody, David J. Adelstein, Jessica L. Geiger, Deborah J. Chute, Jamie A. Ku
Publikováno v:
Head & Neck. 44:2220-2227
We sought to determine whether detection of cartilage invasion (CI) by computed tomography predicts oncologic outcomes after primary total laryngectomy.Retrospective cohort study comparing oncologic outcomes between radiologic versus pathologic diagn
Autor:
Eric Lamarre, Howard Liu, Matthew Schymick, Farzan Siddiqui, Sandro V. Porceddu, Jimmy J. Caudell, Shlomo A. Koyfman, Ahmed I Ghanem, Nikhil P. Joshi, Jamie A. Ku, David J. Adelstein, Joseph Scharpf, Neal Dunlap, Brian B. Burkey, Nancy Y. Lee, Jillian Tsai, Neil M. Woody, Brandon Prendes, L. Schwartzman, Arslan Babar, Jessica L. Geiger
Publikováno v:
Current Oncology, Vol 28, Iss 221, Pp 2409-2419 (2021)
Current Oncology
Volume 28
Issue 4
Pages 221-2419
Current Oncology
Volume 28
Issue 4
Pages 221-2419
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, con
Autor:
TIMOTHY D. SMILE, CHANDANA A. REDDY, BRIAN MATIA, CHRISTOPHER W. FLEMING, CHAIM DOMB, JESSICA L. GEIGER, NIKHIL P. JOSHI, NEIL M. WOODY, DEBORAH J. CHUTE, CHRISTOPHER C. GRIFFITH, DAVID J. ADELSTEIN, SHLOMO A. KOYFMAN
Publikováno v:
Anticancer research. 42(8)
Definitive treatment for locally advanced head and neck squamous cell carcinoma (LAHNSCC) is often compromised in older adults due to concerns about potential treatment toxicity intolerance. We reviewed our institutional experience with definitive ma
Autor:
Maxwell Y. Lee, Mario Belfiglio, Johnathan Zeng, Christopher W. Fleming, Shlomo Koyfman, Nikhil P. Joshi, Eric Lamarre, Brandon Prendes, Joseph Scharpf, Robert R. Lorenz, Neil M. Woody, David J. Adelstein, Jessica L. Geiger, Deborah J. Chute, Jamie A. Ku
Publikováno v:
The LaryngoscopeBIBLIOGRAPHY.
Organ preservation (OP) treatment for advanced laryngeal cancer has increased compared to primary total laryngectomy. Our study compares oncologic and functional outcomes between these approaches.Retrospective cohort study.Single tertiary care instit
Autor:
Brian B. Burkey, David J. Adelstein, David D. Xiong, Daniel R. Carrizosa, Jamie A. Ku, John F. Greskovich, Brandon Prendes, Zvonimir L. Milas, Neil M. Woody, James R. Broughman, Shlomo A. Koyfman, Nikhil P. Joshi, Ashley Sumrall, Benjamin J. Moeller, Jessica L. Geiger, Eric Lamarre, Daniel Brickman, Matthew C. Ward, Kevin J. Contrera, Catherine H. Frenkel
Publikováno v:
Cancer. 126:2784-2790
Background De-intensified treatment strategies for early human papillomavirus-positive (HPV+) oropharynx cancer (OPC) rely on selecting patients with an excellent prognosis. The criterion for enrollment in current de-intensification trials is ≤10 p
Autor:
Robert R. Lorenz, Nikhil P. Joshi, Brian B. Burkey, Shlomo A. Koyfman, John F. Greskovich, Eric Murray, Eric Lamarre, J.M. Sharrett, David J. Adelstein, Joseph Scharpf, Jessica L. Geiger, Matthew C. Ward, Brandon Prendes, Neil M. Woody
Publikováno v:
The Laryngoscope. 130:2372-2377
To investigate the association between tumor volume and locoregional failure (LRF) after concurrent chemoradiation (CCRT) for locally advanced larynx cancer (LC).This is a retrospective cohort study from 2009 to 2014 identified from an institutional
Autor:
Kailin Yang, David J. Adelstein, Matthew C. Ward, Brian B. Burkey, Shlomo A. Koyfman, Roy Xiao, Brandon Prendes
Publikováno v:
Head & Neck. 41:3895-3905
BACKGROUND We investigated the impact of level I lymph node involvement (LNI) on survival for patients with oropharyngeal squamous cell carcinoma (OPSCC). METHODS We performed a cohort study of patients with OPSCC who underwent resection with known h
Autor:
Justin A. Bishop, Deborah J. Chute, Cheng Lu, Patricia Castro, Kaustav Bera, Anant Madabhushi, Kim Ely, Mitra Mehrad, Farhoud Faraji, Wade L. Thorstad, David J. Adelstein, Germán Corredor, James S. Lewis, Shlomo A. Koyfman, Pingfu Fu, Lester D.R. Thompson, Mojgan Mokhtari, Kailin Yang, Paula Toro, Can Fahrettin Koyuncu, Vlad C. Sandulache, Christina Buzzy
Publikováno v:
Journal of the National Cancer Institute. 114(4)
Background Human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) has excellent control rates compared to nonvirally associated OPSCC. Multiple trials are actively testing whether de-escalation of treatment intensity fo